137.00 -0.01 (-0.01%)
After hours: 6:39PM EDT
|Bid||132.00 x 100|
|Ask||137.10 x 100|
|Day's range||129.93 - 137.61|
|52-week range||92.65 - 143.37|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||151.29|
A special FDA committee unanimously approved GW Pharmaceuticals' cannabis-based anti-seizure drug, the firm said midday Thursday.
WASHINGTON (AP) — A medicine made from the marijuana plant moved one step closer to U.S. approval Thursday after federal health advisers endorsed it for the treatment of severe seizures in children with epilepsy.
An FDA advisory panel recommended approval of what could become the first prescription drug in the U.S. derived from the marijuana plant, as a treatment for people with rare forms of epilepsy.
GW Pharmaceuticals PLC said Thursday it has won a unanimous recommendation from a U.S. Food and Drug Administration advisory committee for the approval of its cannabis-derived drug epidiolex. Epidiolex ...
LONDON and CARLSBAD, Calif., April 19, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
Fresh bullishness over the past few trading periods has inspired positive trading in several key global markets. But interestingly enough, a number of optimistic headlines in the budding marijuana industry has led to an even stronger recovery in this popular investing area.
GW Pharma spiked to an 11-week high Tuesday after an internal review hinted at the likelihood the FDA will approve its cannabis-based anti-seizure drug.
WASHINGTON (AP) — A closely watched medicine made from the marijuana plant reduces seizures in children with severe forms of epilepsy and warrants approval in the United States, health officials said Tuesday.
GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.
GW Pharmaceuticals PLC shares surged 10.3% in heavy Tuesday morning trade after the release of positive briefing documents for a Food and Drug Administration advisory committee meeting regarding the company's ...
NEW YORK, April 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
LONDON, April 12, 2018-- GW Pharmaceuticals plc“ GW,”“ the Company” or“ the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...
A series of headlines out of Canada caused a unique selloff in that country's budding marijuana market. With this in mind, let's take a closer look at how a few popular stocks with exposure to the marijuana industry fared during this recent volatility.
A disappointing performance from one of these new drugs hitting the market right now could spell disaster for these stocks. Here's what to look for.
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...